Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
Bullboard Posts
User Avatar Image
(1507)
•••
Comment by wildbird1on Mar 04, 2019 1:03pm
154 Views
Post# 29439184

RE:Good read for us investors in the space!

RE:Good read for us investors in the space!Good article SeekAlpha81...
Has you said no mention of Genenews but nevertheless very interesting...

This article said (QUOTE) Exact Science (NASDAQ:EXAS:US= $87.00USD) is best know for its Cologuard DNA poop test for colorectal cancer, while Cologuard isn't a liquid biopsy test(blood test), the company is also working with the Mayo Clinic to develop Liquid Biopsy (End of QUOTE)

Trying to cath up to develop liquid biopsy(blood tests) can cost a lots of money, that could be one of the reasons that EXAS:US has revenue but no profit.

On the other hand Genenews has 4 cancer tests fully developed, fully functional and ready for market.

In its CC presentation https://Plus.google.com/+WeedWarrior/posts/PH11vherjtss
 Genenews said (QUOTE) We believe that we can be profitable in 2019, with revenue in excess of CDA30 million (End of QUOTE)

Larger investors get very exited when they see the big word PROFIT.






SeekAlpha81 wrote: https://www.fool.com/investing/2019/02/10/the-100-billion-investing-opportunity-that-could-r.aspx

 Unfortunately no mention of Genenews.... but the sector is attracting lots of attention which never hurts!


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities